Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating an investigational drug called ALN-HSD for adults with Metabolic Dysfunction-Associated SteatoHepatitis MASH, a liver condition marked by fat buildup, inflammation, and scarring that can lead to cirrhosis and liver failure. This Phase 2 study aims to understand how ALN-HSD affects liver scarring and inflammation in participants who have genetic risk factors for MASH. Participants are randomly assigned in a 11 ratio to receive either ALN-HSD or a placebo. The study is double-blind and quadruple-masked, meaning neither participants nor researchers know who receives the active drug or placebo. Treatment is administered according to the study protocol over a period of 52 weeks, with follow-up monitoring extending to 84 weeks to assess safety. During the study, participants will undergo various assessments including liver biopsies, blood tests measuring liver enzymes and fibrosis markers, and genetic evaluations. Researchers will track changes in liver fibrosis and inflammation as well as the presence of drug metabolites in blood samples. Safety is monitored throughout the study and beyond the treatment period. The total duration of participation is up to 84 weeks.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating an investigational mRNA seasonal flu vaccine compared to a licensed flu vaccine in adults aged 65 years and older. The study aims to assess the ability of the vaccines to prevent laboratory-confirmed influenza illness, monitor side effects, and measure immune responses during the flu season. This Phase 3 randomized, observer-blind trial is sponsored by GlaxoSmithKline and focuses on flu prevention in older adults. Participants will receive a single injection on Day 1 of either the investigational mRNA seasonal flu vaccine or a licensed, age-appropriate, season-adapted influenza vaccine. The study follows a parallel group design where participants are randomly assigned to one of these two vaccine groups. The follow-up period covers the entire influenza season to assess vaccine efficacy and safety. During the study, participants will be monitored for influenza-like illness confirmed by laboratory tests from Day 15 through the end of the influenza season. Safety assessments include tracking solicited local and systemic side effects from Day 1 to Day 7, unsolicited adverse events up to Day 28, and serious adverse events or special interest adverse events through at least 180 days of follow-up. Blood samples will be collected before dosing and on Day 29 to evaluate immune responses. Participants are followed for safety and efficacy throughout the flu season, with total involvement spanning several months.
Actively Recruiting
Bipolar disorder is a serious, long-lasting mood condition affecting both adults and children. This research focuses on studying the effects and safety of cariprazine, a medication approved for adults, in treating depressive episodes linked to bipolar I disorder in children and adolescents aged 10 to 17. The study aims to better understand how this drug impacts the pediatric population, where treatment options are currently limited. Participants will be randomly assigned to one of two groups one receiving cariprazine at flexible doses adjusted by age and weight, and the other receiving a placebo. The treatment lasts six weeks, with dose adjustments at week 3 depending on response. Following treatment, there is a four-week safety follow-up period. Weekly visits at clinics or hospitals will support monitoring and treatment. During the study, participants will undergo medical assessments, blood tests, questionnaires, and side effect checks to evaluate the drugs impact. Researchers will track changes in mood symptoms using scales like the Childrens Depression Rating Scale and monitor safety through vital signs, lab tests, and movement assessments. The total study participation spans around 10 weeks, including treatment and follow-up.
Actively Recruiting
This research aims to evaluate the safety and effectiveness of atogepant, a medication currently approved for adults, in treating episodic migraine in children aged 6 to 17 years. The study focuses on pediatric participants who experience moderate to severe migraines with symptoms such as throbbing head pain, nausea, and sensitivity to light and sound. Limited treatment options exist for this age group, so the trial investigates different doses of atogepant to address this need. Participants are divided into groups based on age and receive either a placebo or low or high doses of atogepant tablets once daily for 12 weeks. Children aged 6 to 11 first undergo an open-label pharmacokinetic substudy to determine the appropriate dose before the double-blind treatment period. After the initial 12 weeks, participants either have a follow-up visit 4 weeks after their last dose or can continue receiving atogepant for an additional 52 weeks in an extension study. Throughout the study, participants attend regular visits at hospitals or clinics for medical assessments, blood tests, and questionnaires to monitor the effects of treatment and check for side effects. The main outcomes measured include changes in monthly migraine days and safety through adverse event tracking. The study plans to enroll about 450 children worldwide, with comprehensive monitoring over the treatment and follow-up periods.
Actively Recruiting
Researchers are evaluating the effectiveness of AXS-05 compared to bupropion in preventing the return of depressive symptoms in adults with major depressive disorder MDD who have already responded to treatment with AXS-05. This is a randomized, double-blind, active-controlled study conducted across multiple centers, aiming to assess relapse prevention in people diagnosed with MDD without psychotic features. Participants will first receive open-label AXS-05 treatment for up to 10 weeks, during which their response and remission will be monitored. Those who meet response and remission criteria will then be randomly assigned to continue taking AXS-05 or switch to bupropion tablets, both taken twice daily, for a double-blind treatment period lasting up to 26 weeks or until depressive symptoms relapse. Throughout the study, participants will be closely monitored for signs of depressive symptom relapse using regular assessments. The main outcome measured is the time from randomization to relapse over the 26-week double-blind period. The entire study period includes an initial 10-week treatment phase followed by up to 26 weeks of randomized treatment, with ongoing evaluation by the study team to track safety and treatment effects.
Actively Recruiting
Researchers are evaluating the effectiveness of osavampator compared to a placebo as an additional treatment to delay the return of depressive symptoms in adults with major depressive disorder MDD. This Phase 3 study focuses on maintaining treatment effects in participants diagnosed with recurrent moderate or severe MDD or persistent depressive disorder who have not responded adequately to oral antidepressants. The study aims to understand whether osavampator can help prevent relapse in this population. Participants will first receive osavampator during an initial open-label treatment phase. Following this, they will be randomly assigned to receive either osavampator or a matching placebo during a double-blind maintenance period. Both treatments are given as oral tablets, and participants will continue their existing oral antidepressants at the same dose and frequency throughout the study. The study may last up to approximately 32 months from randomization. During the study, participants will be regularly monitored for relapse of depressive symptoms using the Hamilton Depression Rating Scale. Researchers will track the time from randomization to relapse or the end of the study to assess treatment maintenance. Safety and adherence will be evaluated throughout, with participants expected to comply with study procedures and restrictions. The total duration of participation varies but can extend up to nearly three years.
Actively Recruiting
Researchers are evaluating the efficacy and safety of VER-01, a full-spectrum cannabis extract, in adults with chronic painful lumbosacral radiculopathy who have not achieved sufficient pain relief from non-opioid analgesics or cannot use them due to contraindications or intolerance. This phase 3, randomized, double-blind, placebo-controlled trial aims to compare VER-01 to placebo in reducing pain over 12 weeks. The study is sponsored by Vertanical GmbH and uses a parallel design with multiple arms. Participants will be randomly assigned to receive one of two doses of VER-01 or a placebo. VER-01 is a standardized soft extract from Cannabis sativa containing 19 mg of 9-Tetrahydrocannabinol THC per ml. The study lasts 12 weeks of treatment, during which participants will follow a treatment plan, attend scheduled visits, and record information in an electronic diary. The trial includes careful monitoring of safety and efficacy throughout the treatment period. Participants will be involved in scheduled visits and required to comply with the treatment plan and use of an electronic diary. Researchers will assess pain reduction from baseline to week 12 as the primary outcome. Safety evaluations will monitor for any adverse effects. The total participation duration covers the 12-week treatment period, with assessments focused on pain relief and treatment tolerability.
Actively Recruiting
Researchers are conducting a Phase 3, multi-center, randomized, double-blind, placebo-controlled trial to evaluate the safety and effectiveness of solriamfetol in children aged 6 to under 12 years diagnosed with Attention Deficit Hyperactivity Disorder ADHD. The study aims to compare two different doses of solriamfetol against a placebo over a 6-week period. Participants will be randomly assigned to one of three groups solriamfetol dose A, solriamfetol dose B, or placebo. Each participant will take capsules once daily for up to 6 weeks. The study uses a parallel group design where participants receive only one of the study treatments. During the trial, children will be monitored regularly to assess changes in ADHD symptoms using the ADHD Rating Scale-5 ADHD-RS-5 total score from the start of the study to week 6. Safety and adherence to the study treatment will also be evaluated throughout the trial. The total participation duration is up to 6 weeks.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of solriamfetol in adolescents aged 12 to less than 18 years diagnosed with Attention Deficit Hyperactivity Disorder ADHD. This Phase 3, multi-center, randomized, double-blind, placebo-controlled study lasts for 6 weeks and aims to compare two different doses of solriamfetol against a placebo. Participants will be randomly assigned to one of three groups solriamfetol dose A, solriamfetol dose B, or placebo. Each participant will take their assigned capsules once daily for up to 6 weeks. The study uses a parallel-group design, meaning each participant remains in their assigned group throughout the trial. During the trial, participants will be monitored regularly to assess changes in their ADHD symptoms using a standard rating scale. Safety and adherence to the study medication will be closely observed. The primary outcome measured is the change in the ADHD-RS-5 total score from the beginning of the study to week 6, reflecting the treatments effect on ADHD symptoms over the course of the trial.
Actively Recruiting
Migraine is a common neurological disorder causing moderate to severe headaches often accompanied by nausea, vomiting, and sensitivity to light and sound. This research aims to evaluate the safety and effectiveness of ubrogepant, a medication approved for adults, in treating acute migraine attacks in children and adolescents aged 6 to 17 years. The study includes two groups a pharmacokinetic PK cohort for younger children and a main randomized study involving both children and adolescents. Participants aged 6 to 11 in the PK cohort will receive two different doses of ubrogepant to determine the appropriate dose for the main study. In the main study, after dose selection, children aged 6 to 11 and adolescents aged 12 to 17 will be randomly assigned to receive either a low dose, high dose of ubrogepant, or placebo, with a 1 in 3 chance of placebo assignment. For qualifying migraine attacks, participants will take oral tablets of the assigned study intervention and may take a second dose or rescue medication at least 2 hours later if the headache persists. Participants will attend regular visits at a hospital or clinic for up to 6 months. Researchers will monitor the effects of treatment through medical assessments, blood tests, side effect checks, and questionnaires. The main outcome measured is the percentage of participants who are free from pain 2 hours after the initial dose. Safety and tolerability will also be assessed throughout the study duration.